knowledge -WSS

knowledge

author：Wikipedia 2025-09-06 03:26:16 - browse：64

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Wegovy cuts risk of cardiovascular events by 20%, study finds

WSS

Removing probiotics from the NICU could threaten preemies' health

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

‘The Bear’ and hospitality in hospitals

Extreme heat events are a public health emergency

White House calls on federal agencies to crack down on AI abuses

Ambulance rides for just $100? Advisers want major billing fixes

hotspot

knowledge

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Germany receives 178 compensation applications from gay servicepeople over discrimination

At least 13 dead in Texas as scorching temps continue

Former Georgia lieutenant governor says he received grand jury subpoena

In Memoriam: Notable people who died in 2023

Free speech concerns arise in wake of journal editor Eisen's firing

Bright Health sells Medicare Advantage business to Molina

Biotech incubator Curie.Bio graduates its first startup

At least 13 dead in Texas as scorching temps continue

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

focus

Study: New antibiotic targets gonorrhea as well as last existing drug

More doctors should go into startup world

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

White House calls on federal agencies to crack down on AI abuses

Abortion clinic in Cancun will cater to Americans

The new shift in health care is toward less care

focus

leisure time

leisure time

hotspot